{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:43:20Z","timestamp":1793234600560,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04222-x","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T16:06:58Z","timestamp":1771344418000},"page":"3304-3312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neutrophil-to-lymphocyte ratio in unresectable or metastatic esophageal squamous cell carcinoma: a systematic review, meta-analysis and meta-regression"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0903-6793","authenticated-orcid":false,"given":"Giuseppe Antonio","family":"Colloca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Venturino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"4222_CR1","unstructured":"ECIS\u2014European Cancer Information System. https:\/\/ecis.jrc.ec.europa.eu. Last accessed on 29 Sept 2024"},{"issue":"3","key":"4222_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan E, Soerjomataram I, Rumgay H, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterol. 2022;163(3):649\u201358.","journal-title":"Gastroenterol"},{"key":"4222_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/10732748211072976","volume":"29","author":"M Shi","year":"2022","unstructured":"Shi M, Zhai G-Q. Models for predicting early death in patients with stage IV esophageal cancer: a surveillance, epidemiology, and end results-based cohort study. Cancer Control. 2022;29:1\u201311.","journal-title":"Cancer Control"},{"issue":"5","key":"4222_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449\u201362.","journal-title":"N Engl J Med"},{"issue":"10","key":"4222_CR5","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916\u201325.","journal-title":"JAMA"},{"key":"4222_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41591-024-02797-y","volume":"30","author":"J Li","year":"2024","unstructured":"Li J, Chen Z, Bai Y, Liu B, Li Q, Zhang J, et al. First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. Nat Med. 2024;30:740\u20138.","journal-title":"Nat Med"},{"issue":"10302","key":"4222_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371.","journal-title":"Lancet"},{"key":"4222_CR8","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.21.01926","volume":"40","author":"L Shen","year":"2022","unstructured":"Shen L, Kato K, Kim S-B, Ajani JA, Zhao K, He Z, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol. 2022;40:3065\u201376.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4222_CR9","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.21037\/tcr-23-1117","volume":"12","author":"S El Khatib","year":"2023","unstructured":"El Khatib S, Saeed A. Unraveling the puzzle: efficacy of PD-L1 inhibitors in esophageal squamous cell carcinomas with low PD-L1 expression\u2014a comprehensive overview of chellenges and limitations. Transl Cancer Res. 2023;12(12):3245\u20138.","journal-title":"Transl Cancer Res"},{"key":"4222_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068714","volume":"377","author":"Z Lu","year":"2022","unstructured":"Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, et al. Sintilimab versus placebo in combination with chemotherapy as first-line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377:e068714.","journal-title":"BMJ"},{"issue":"6","key":"4222_CR11","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1245\/s10434-021-09637-0","volume":"28","author":"S Hoshino","year":"2021","unstructured":"Hoshino S, Takeuchi M, Kawakubo H, Matsuda S, Mayanagi S, Irino T, et al. Usefulness of neutrophil to lymphocyte ratio at recurrence for predicting long-term outcomes in patients with recurrent esophageal squamous cell carcinoma. Ann Surg Oncol. 2021;28(6):3001\u20138.","journal-title":"Ann Surg Oncol"},{"key":"4222_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/15330338211070140","volume":"21","author":"B Li","year":"2022","unstructured":"Li B, Xiong F, Yi S, Wang S. Prognostic and clinicopathologic significance of neutrophil-to-lymphocyte ratio in esophageal cancer: an update meta-analysis. Technol Cancer Res Treat. 2022;21:15330338211070140.","journal-title":"Technol Cancer Res Treat"},{"key":"4222_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/MD.0000000000013585","volume":"97","author":"X Zhang","year":"2018","unstructured":"Zhang X, Jiang Y, Wang Y, Wang Z, Zhao L, Xue X, et al. Prognostic role of neutrophil-lymphocyte ratio in esophageal cancer. A systematic review and meta-analysis. Medicine. 2018;97:49.","journal-title":"Medicine"},{"issue":"4","key":"4222_CR14","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.21037\/tcr.2019.06.15","volume":"8","author":"X Li","year":"2019","unstructured":"Li X, Zhang H, Jia X, Xu L, Liu H, Chen L, et al. Survival benefit of radiotherapy in metastatic esophageal cancer: a population-based study. Transl Cancer Res. 2019;8(4):1074\u201385.","journal-title":"Transl Cancer Res"},{"key":"4222_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1353445","volume":"15","author":"L Gao","year":"2024","unstructured":"Gao L, Tang L, Peng J, Hu Z, Yang J, Liu B. PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study. Front Immunol. 2024;15:1353445.","journal-title":"Front Immunol"},{"key":"4222_CR16","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1186\/s12885-023-11568-w","volume":"23","author":"K Sugawara","year":"2023","unstructured":"Sugawara K, Oka D, Hara H, Yoshii T, Ushijima H, Kudo S, et al. Survival outcomes of esophageal cancer patients with recurrence after curative treatments. BMC Cancer. 2023;23:1051.","journal-title":"BMC Cancer"},{"issue":"6","key":"4222_CR17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/00365521.2024.2319319","volume":"59","author":"M Fu","year":"2024","unstructured":"Fu M, Li Z, Ma J, Shen F, Zhang X. Study on the predictive value of pretreatment peripheral blood inflammatory markers regarding immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma. Scand J Gastroenterol. 2024;59(6):722\u20139.","journal-title":"Scand J Gastroenterol"},{"key":"4222_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41467-022-28408-3","volume":"13","author":"J Xu","year":"2022","unstructured":"Xu J, Li Y, Fan Q, Shu Y, Yang L, Cui T, et al. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). Nat Commun. 2022;13:857.","journal-title":"Nat Commun"},{"issue":"1","key":"4222_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.21037\/jgo-23-48","volume":"14","author":"M Wu","year":"2023","unstructured":"Wu M, Zhu Y, Chen X, Wang X, Lin X, Yan X, et al. Prognostic nutritional index predicts the prognosis of patients with advanced esophageal cancer treated with immune checkpoint inhibitors: a retrospective cohort study. J Gastrointest Oncol. 2023;14(1):54\u201363.","journal-title":"J Gastrointest Oncol"},{"key":"4222_CR20","first-page":"332","volume":"9","author":"JH Park","year":"2019","unstructured":"Park JH, Woodley N, McMillan DC, Glen P. Palliative stenting for oesophagogastric cancer: tumour and host factors and prognosis. Support Care Cancer. 2019;9:332\u20139.","journal-title":"Support Care Cancer"},{"key":"4222_CR21","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1111\/1759-7714.14486","volume":"13","author":"C Cui","year":"2022","unstructured":"Cui C, Wu X, Deng L, et al. Modified Glasgow prognostic score predicts the prognosis of patients with advanced esophageal squamous cell carcinoma: a propensity score-matched analysis. Thorac Cancer. 2022;13:2041\u20139.","journal-title":"Thorac Cancer"},{"key":"4222_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02856-3","volume":"23","author":"H-K Wang","year":"2023","unstructured":"Wang H-K, Wei Q, Yang Y-L, Lu T-Y, Yan Y, Wang F. Clinical usefulness of the lymphocyte-to-monocyte ratio and aggregate index of systemic inflammation in patients with esophageal cancer: a retrospective cohort study. Cancer Cell Int. 2023;23:13.","journal-title":"Cancer Cell Int"},{"key":"4222_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"key":"4222_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/cas.13127","volume":"108","author":"T Kijima","year":"2017","unstructured":"Kijima T, Arigami T, Uchilkado Y, Uenosono Y, Kita Y, Owaki T, et al. Combined fibrinogen and neutrophil-lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma. Cancer Sci. 2017;108:193\u20139.","journal-title":"Cancer Sci"},{"key":"4222_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/CMAR.S147324","volume":"10","author":"S-B Zhou","year":"2018","unstructured":"Zhou S-B, Guo X-W, Gu L, Ji S-J. Influential factors on radiotherapy efficacy and prognosis in patients with secondary lymph node metastasis after esophagectomy of thoracic esophageal squamous cell carcinoma. Cancer Manage Res. 2018;10:217\u201325.","journal-title":"Cancer Manage Res"},{"key":"4222_CR26","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.21873\/anticanres.13765","volume":"39","author":"J-C Guo","year":"2019","unstructured":"Guo J-C, Lin C-C, Lin C-Y, Hsieh M-S, Kuo H-Y, Lien M-Y, et al. Neutrophil-to-lymphocyte ratio and use of antibiotics associated with prognosis in esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitors. Anticancer Res. 2019;39:5675\u201382.","journal-title":"Anticancer Res"},{"key":"4222_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.834564","volume":"12","author":"Y Gao","year":"2022","unstructured":"Gao Y, Zhang Z, Li Y, Chen S, Lu J, Wu L, et al. Pretreatment neutrophil-to-lymphocyte ratio as a prognostic biomarker in unresectable or metastatic esophageal cancer patients with anti-PD-1 therapy. Front Oncol. 2022;12:834564.","journal-title":"Front Oncol"},{"key":"4222_CR28","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2147\/OTT.S382967","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu J, Gao D, Li J, Hu G, Liu J, Liu D. The predictive value of systemic inflammatory factors in advanced, metastatic esophageal squamous cell carcinoma patients treated with camrelizumab. OncoTargets Ther. 2022;15:1161\u201370.","journal-title":"OncoTargets Ther"},{"key":"4222_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1144875","volume":"13","author":"L Da","year":"2023","unstructured":"Da L, Qu Z, Zhang C, Shen Y, Huang W, Zhang Y, et al. Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment. Front Oncol. 2023;13:144875.","journal-title":"Front Oncol"},{"key":"4222_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1195848","volume":"13","author":"N Li","year":"2023","unstructured":"Li N, Gao L, Ge Y, Zhao L, Bai C, Wang Y. Prognostic and predictive significance of circulating biomarkers in patients with advanced upper gastrointestinal cancer undergoing systemic chemotherapy. Front Oncol. 2023;13:1195848.","journal-title":"Front Oncol"},{"key":"4222_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225421","volume":"15","author":"C-P Pai","year":"2023","unstructured":"Pai C-P, Chien L-I, Huang C-S, Hsu H-S, Hsu P-K. Treatment outcomes and risk factors for incomplete treatment after definitive chemoradiotherapy for non-resectable or metastatic esophageal cancer. Cancers. 2023;15:5421.","journal-title":"Cancers"},{"key":"4222_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17588359231169981","volume":"15","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Yang L, Wang D, Ruan Y, Zhang J, Zhao L, et al. Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma. Ther Adv Med Oncol. 2023;15:1\u201320.","journal-title":"Ther Adv Med Oncol"},{"key":"4222_CR33","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.2147\/JIR.S450669","volume":"17","author":"H Shang","year":"2024","unstructured":"Shang H, Chen Y, Wang Q, Yang Y, Zhang J. A correlation evaluation between the peripheral blood index and the prognosis of advanced esophageal squamous cell carcinoma patients treated with camrelizumab. J Inflamm Res. 2024;17:2009\u201321.","journal-title":"J Inflamm Res"},{"key":"4222_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/15330338211070140","volume":"21","author":"B Li","year":"2022","unstructured":"Li B, Xiong F, Yi S, Wang S. Prognostic and clinicopathologic significance of neutrophil-to-lymphocyte ratio in esophageal cancer: an update meta-analysis. Tech Cancer Res Treat. 2022;21:1\u201311.","journal-title":"Tech Cancer Res Treat"},{"key":"4222_CR35","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2147\/CMAR.S150350","volume":"9","author":"S-G Wu","year":"2017","unstructured":"Wu S-G, Zhang W-W, He Z-Y, Sun J-Y, Chen Y-X, Guo L. Sites of metastasis and overall survival in esophageal cancer: a population-based study. Cancer Manag Res. 2017;9:781\u20138.","journal-title":"Cancer Manag Res"},{"issue":"6","key":"4222_CR36","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, et al. Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832\u201342.","journal-title":"Lancet Oncol"},{"key":"4222_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68160-6","volume":"10","author":"B Li","year":"2020","unstructured":"Li B, Wang R, Zhang T, Sun X, Jiang C, Li W, et al. Development and validation of a nomogram prognostic model for esophageal cancer patients with oligometastases. Sci Rep. 2020;10:11259.","journal-title":"Sci Rep"},{"issue":"21","key":"4222_CR38","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.7150\/jca.27579","volume":"9","author":"M Liu","year":"2018","unstructured":"Liu M, Wang C, Gao L, Lv C, Cai X. A nomogram to predict long-time survival for patients with M1 diseases of esophageal cancer. J Cancer. 2018;9(21):3986\u201390.","journal-title":"J Cancer"},{"issue":"6","key":"4222_CR39","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.athoracsur.2021.03.002","volume":"112","author":"TB Nobel","year":"2021","unstructured":"Nobel TB, Sihag S, Xing XX, Eljalby M, Hsu M, Tan KS, et al. Oligometastases after curative esophagectomy are not one-size-fits-all. Ann Thorac Surg. 2021;112(6):1775\u201381.","journal-title":"Ann Thorac Surg"},{"key":"4222_CR40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.athoracsur.2020.08.034","volume":"112","author":"SN Seyedin","year":"2021","unstructured":"Seyedin SN, Parekh KR, Ginader T, Caster JM. The role of definitive radiation and surgery in metastatic esophageal cancer: an NCDB investigation. Ann Thorac Surg. 2021;112:459\u201366.","journal-title":"Ann Thorac Surg"},{"key":"4222_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.783752","volume":"12","author":"H Yang","year":"2022","unstructured":"Yang H, Wang K, Li Y, Li S, Yuan L, Ge H. Local ablative treatment improves survival in ESCC patients with specific metastases, 2010\u20132016: a population-based SEER analysis. Front Oncol. 2022;12:783752.","journal-title":"Front Oncol"},{"key":"4222_CR42","volume":"3","author":"PL Zhan","year":"2022","unstructured":"Zhan PL, Canavan ME, Erner T, Pichert MD, Li AX, Maduka RC, et al. Nonregional lymph nodes ad the only metastatic site in stage IV esophageal cancer. JTO Clin Res Rep. 2022;3:100426.","journal-title":"JTO Clin Res Rep"},{"issue":"4","key":"4222_CR43","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.21037\/jtd.2019.03.10","volume":"11","author":"Y Chen","year":"2019","unstructured":"Chen Y, Cheng X, Song H, Wu AJ, Ku GY, Lee P, et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases. J Thorac Dis. 2019;11(4):1536\u201345.","journal-title":"J Thorac Dis"},{"issue":"3","key":"4222_CR44","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/COC.0000000000000066","volume":"39","author":"J Wang","year":"2016","unstructured":"Wang J, Suri JS, Allen PK, et al. Factors predictive of improved outcomes with multimodality local therapy after palliative chemotherapy for stage IV esophageal cancer. Am J Clin Oncol. 2016;39(3):228\u201335.","journal-title":"Am J Clin Oncol"},{"key":"4222_CR45","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.21037\/tcr-21-1128","volume":"10","author":"G Qiu","year":"2021","unstructured":"Qiu G, Zhang H, Wang F, Zheng Y, Wang Y. Patterns of metastasis and prognosis of elderly esophageal squamous cell carcinoma patients stage IVB: a population-based study. Transl Cancer Res. 2021;10:4591\u2013600.","journal-title":"Transl Cancer Res"},{"issue":"2","key":"4222_CR46","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.annonc.2019.10.018","volume":"31","author":"M Moehler","year":"2020","unstructured":"Moehler M, Maderer A, Thuss-Patience PC, et al. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO\/EORTC trial (POWER). Ann Oncol. 2020;31(2):228\u201335.","journal-title":"Ann Oncol"},{"key":"4222_CR47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10388-021-00878-2","volume":"19","author":"K Kudou","year":"2022","unstructured":"Kudou K, Saeki H, Nakashima Y, Kimura Y, Oki E, Mori M, et al. Clinical outcomes of surgical resection for recurrent lesion after curative esophagectomy for esophageal squamous cell carcinoma: a nationwide, large-scale retrospective study. Esophagus. 2022;19:57\u201368.","journal-title":"Esophagus"},{"key":"4222_CR48","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3390\/cancers15051472","volume":"15","author":"Y Yamauchi","year":"2023","unstructured":"Yamauchi Y, Nakajima J, Mun M, Shintani Y, Kuroda H, Iwata T, et al. Survival after lung metastasectomy from esophageal cancer: results from a multi-institutional database. Cancers. 2023;15:1472.","journal-title":"Cancers"},{"key":"4222_CR49","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11748-014-0444-4","volume":"62","author":"M Watanabe","year":"2014","unstructured":"Watanabe M, Mine S, Yamada K, Shigaki H, Baba Y, Yoshida N, et al. Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus. Gen Thorac Cardiovasc Surg. 2014;62:685\u201392.","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"4222_CR50","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1245\/s10434-019-07654-8","volume":"27","author":"T Yokota","year":"2020","unstructured":"Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, et al. A 3-year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Ann Surg Oncol. 2020;27:460\u20137.","journal-title":"Ann Surg Oncol"},{"key":"4222_CR51","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/jjco\/hyz112","volume":"49","author":"M Terada","year":"2019","unstructured":"Terada M, Hara H, Daiko H, Mizusawa J, Kadota T, Hori K, et al. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510:TRIANGlE). Jpn J Clin Oncol. 2019;49:1055\u201360.","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"4222_CR52","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/bmjspcare-2017-001490","volume":"9","author":"JH Park","year":"2019","unstructured":"Park JH, Woodley N, McMillan DC, Glen P. Palliative stenting for oesophagogastric cancer: tumour and host factors and prognosis. BMJ Support Palliat Care. 2019;9(3):332\u20139.","journal-title":"BMJ Support Palliat Care"},{"issue":"7636","key":"4222_CR53","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","volume":"541","author":"CGARN","year":"2017","unstructured":"CGARN. Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169\u201375.","journal-title":"Nature"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04222-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04222-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04222-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T12:02:18Z","timestamp":1784980938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04222-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4222"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04222-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any interventional studies with human participants performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}